[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZbAOO-SiWw-qXjHCusVaQei7O6nemDbI7VZF_JiXhRk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Centre Hospitalier Universitaire de Saint Etienne",[4],583,false,123,25,872067,33,475,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Healthy",23,{"name":18,"count":19},"Aging",11,{"name":21,"count":19},"Cancer",{"name":23,"count":19},"Healthy Volunteers",{"name":25,"count":26},"Neuropathic Pain",8,{"name":28,"count":26},"Schizophrenia",{"name":30,"count":26},"Stroke",{"name":32,"count":33},"Anorexia Nervosa",7,[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04384341","Haemophilia and Bone Loss - PHILEOS Study","2025-03","Blood sampling for patients only",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06368856","Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study","2025-03-04","Mupirocin",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06594250","Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia","2025-11","Venous sampling",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06824779","Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses","2025-12-19","Flu Vaccine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04030676","QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis","2026-01","Blood samples",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04374175","SERum-bank for PANcreatic Cancer","2026-01-01","Blood sample",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05340023","Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension","2026-06","blood sample",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05742321","Analysis of the Genotype\u002FPhenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France","2026-06-01","Genotyping",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT04053855","Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma","2026-08-01","Urinary sample",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06528431","Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","2026-09-19","Clinical tapering strategy",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,136,167,193,217,235,258,276,303,321,348,366,391,409,457,483,501,524,542,682,749,789,813,838,865,887,908,935,953,978,996,1019,1037,1055,1092,1117,1144,1162,1180,1205,1230,1255,1273,1301,1319,1343,1368,1394,1412,1439,1457,1481,1504,1522,1549,1567,1592,1644,1680,1709,1737,1755,1773,1800,1818,1845,1869,1887,1912,1938,1964,1982,2000,2024,2042,2068,2086,2109,2135,2153,2178,2196,2214,2232,2258,2283,2312,2330,2348,2366,2393,2411,2436,2464,2482,2509,2534,2560,2578,2601,2619,2637,2655,2673,2699,2717,2735,2759,2777,2811,2846,2871,2898,2923,2941,2966,2989,3016,3041,3067,3090,3115,3138,3163,3181,3206,3229,3247,3273],{"intervention":94,"totalTrials":95,"cells":96},"Adalimumab",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":134},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108,121],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT06180382","Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.","RECRUITING",[90],"2027-10-31","2028-10-31","2024-10-31",220,[118],"Crohn's Disease",[94,120],"Vedolizumab",{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":133},"NCT06390436","Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis","NOT_YET_RECRUITING",[90],"2028-05","2029-05","2025-06",320,[131,132],"Uveitis","Chronic Disease",[94],{"trials":135,"activeCount":99},[],{"intervention":120,"totalTrials":95,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":165},{"trials":139,"activeCount":99},[],{"trials":141,"activeCount":99},[],{"trials":143,"activeCount":99},[],{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":164,"soonestReadout":113},[148,160],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT02768532","Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease","TERMINATED",[90],"2022-01-11","2023-01-23","2016-07-01",47,[158],"Crohn Disease",[120],{"nctId":109,"briefTitle":110,"status":111,"phases":161,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":162,"interventions":163},[90],[118],[94,120],1,{"trials":166,"activeCount":99},[],{"intervention":168,"totalTrials":164,"cells":169},"Biological tests",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":191},{"trials":171,"activeCount":99},[],{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":99},[],{"trials":177,"activeCount":99},[],{"trials":179,"activeCount":164,"soonestReadout":184},[180],{"nctId":181,"briefTitle":182,"status":111,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":190},"NCT06706102","Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome",[90],"2027-09","2027-11","2025-07-02",60,[189],"Immune Effector Cell Associated Neurotoxicity Syndrome",[168],{"trials":192,"activeCount":99},[],{"intervention":54,"totalTrials":164,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":215},{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":164,"soonestReadout":53},[205],{"nctId":51,"briefTitle":52,"status":206,"phases":207,"primaryCompletion":53,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"ACTIVE_NOT_RECRUITING",[90],"2026-03","2025-12-05",30,[212,54],"Volunteers",[54,214],"Biological samples",{"trials":216,"activeCount":99},[],{"intervention":214,"totalTrials":164,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":99},[],{"trials":228,"activeCount":164,"soonestReadout":53},[229],{"nctId":51,"briefTitle":52,"status":206,"phases":230,"primaryCompletion":53,"completion":208,"start":209,"enrollment":210,"conditions":231,"interventions":232},[90],[212,54],[54,214],{"trials":234,"activeCount":99},[],{"intervention":84,"totalTrials":164,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":256},{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":164,"soonestReadout":83},[247],{"nctId":81,"briefTitle":82,"status":111,"phases":248,"primaryCompletion":83,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},[90],"2027-12-19","2024-12-19",180,[253],"Arthritis, Rheumatoid",[84,255],"Step Wedge trial",{"trials":257,"activeCount":99},[],{"intervention":255,"totalTrials":164,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":274},{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":99},[],{"trials":265,"activeCount":99},[],{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":164,"soonestReadout":83},[270],{"nctId":81,"briefTitle":82,"status":111,"phases":271,"primaryCompletion":83,"completion":249,"start":250,"enrollment":251,"conditions":272,"interventions":273},[90],[253],[84,255],{"trials":275,"activeCount":99},[],{"intervention":277,"totalTrials":164,"cells":278},"Early intervention",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":301},{"trials":280,"activeCount":99},[],{"trials":282,"activeCount":99},[],{"trials":284,"activeCount":99},[],{"trials":286,"activeCount":99},[],{"trials":288,"activeCount":164,"soonestReadout":293},[289],{"nctId":290,"briefTitle":291,"status":111,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":299},"NCT06822907","Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults",[90],"2028-10-01","2025-12-17",1052,[297,298],"Acute Febrile Illness","Pneumococcal Infections",[277,300],"Delayed intervention",{"trials":302,"activeCount":99},[],{"intervention":300,"totalTrials":164,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":306,"activeCount":99},[],{"trials":308,"activeCount":99},[],{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":164,"soonestReadout":293},[315],{"nctId":290,"briefTitle":291,"status":111,"phases":316,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":317,"interventions":318},[90],[297,298],[277,300],{"trials":320,"activeCount":99},[],{"intervention":322,"totalTrials":164,"cells":323},"Rituximab",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":344,"NA":346},{"trials":325,"activeCount":99},[],{"trials":327,"activeCount":99},[],{"trials":329,"activeCount":99},[],{"trials":331,"activeCount":164,"soonestReadout":336},[332],{"nctId":333,"briefTitle":334,"status":111,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":342},"NCT05136976","Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders",[89],"2027-12","2028-12","2023-06-29",90,[341],"Anti-MAG Neuropathy",[322,343],"Premedications",{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":99},[],{"intervention":343,"totalTrials":164,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":362,"NA":364},{"trials":351,"activeCount":99},[],{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":164,"soonestReadout":336},[358],{"nctId":333,"briefTitle":334,"status":111,"phases":359,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":360,"interventions":361},[89],[341],[322,343],{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":99},[],{"intervention":367,"totalTrials":164,"cells":368},"Full-dose anticoagulant therapy",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":387,"NA":389},{"trials":370,"activeCount":99},[],{"trials":372,"activeCount":99},[],{"trials":374,"activeCount":99},[],{"trials":376,"activeCount":164,"soonestReadout":336},[377],{"nctId":378,"briefTitle":379,"status":111,"phases":380,"primaryCompletion":336,"completion":337,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT05627375","Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets",[89],"2023-08-16",1400,[384],"Venous Thromboembolic Disease",[367,386],"Antiplatelet therapy",{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"intervention":386,"totalTrials":164,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":405,"NA":407},{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":164,"soonestReadout":336},[401],{"nctId":378,"briefTitle":379,"status":111,"phases":402,"primaryCompletion":336,"completion":337,"start":381,"enrollment":382,"conditions":403,"interventions":404},[89],[384],[367,386],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"intervention":410,"totalTrials":411,"cells":412},"Hydroxychloroquine",3,{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":430,"PHASE4":453,"NA":455},{"trials":414,"activeCount":99},[],{"trials":416,"activeCount":99},[],{"trials":418,"activeCount":164,"soonestReadout":423},[419],{"nctId":420,"briefTitle":421,"status":124,"phases":422,"primaryCompletion":423,"completion":424,"start":128,"enrollment":425,"conditions":426,"interventions":428},"NCT06350630","Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study",[88],"2027-12-31","2030-12-31",334,[427],"IgA Nephropathy",[429],"Hydroxychloroquine Oral",{"trials":431,"activeCount":99},[432,441],{"nctId":433,"briefTitle":434,"status":151,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":33,"conditions":438,"interventions":440},"NCT04522466","Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients",[89],"2020-05-28","2020-04-03",[439],"Sars-CoV2",[410],{"nctId":442,"briefTitle":443,"status":151,"phases":444,"primaryCompletion":445,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":451},"NCT04328285","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers",[89],"2020-05-13","2022-03-30","2020-04-14",118,[450],"COVID-19",[410,452],"Lopinavir and ritonavir",{"trials":454,"activeCount":99},[],{"trials":456,"activeCount":99},[],{"intervention":458,"totalTrials":164,"cells":459},"CAR-T cells",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":164,"soonestReadout":470},[466],{"nctId":467,"briefTitle":468,"status":124,"phases":469,"primaryCompletion":470,"completion":471,"start":73,"enrollment":472,"conditions":473,"interventions":475},"NCT07612787","A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma",[88],"2028-01-01","2031-01-01",44,[474],"Myeloma Multiple",[458,476],"BCMA bispecific",{"trials":478,"activeCount":99},[],{"trials":480,"activeCount":99},[],{"trials":482,"activeCount":99},[],{"intervention":476,"totalTrials":164,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":486,"activeCount":99},[],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":164,"soonestReadout":470},[491],{"nctId":467,"briefTitle":468,"status":124,"phases":492,"primaryCompletion":470,"completion":471,"start":73,"enrollment":472,"conditions":493,"interventions":494},[88],[474],[458,476],{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[],{"intervention":44,"totalTrials":164,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":516,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":504,"activeCount":99},[],{"trials":506,"activeCount":164,"soonestReadout":43},[507],{"nctId":41,"briefTitle":42,"status":206,"phases":508,"primaryCompletion":43,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":514},[87],"2025-12","2024-02-29",40,[15,513],"Staphylococcus Aureus Infection",[44,44,515],"blood samples after Single dose part",{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":99},[],{"intervention":515,"totalTrials":164,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":164,"soonestReadout":43},[530],{"nctId":41,"briefTitle":42,"status":206,"phases":531,"primaryCompletion":43,"completion":509,"start":510,"enrollment":511,"conditions":532,"interventions":533},[87],[15,513],[44,44,515],{"trials":535,"activeCount":99},[],{"trials":537,"activeCount":99},[],{"trials":539,"activeCount":99},[],{"trials":541,"activeCount":99},[],{"intervention":64,"totalTrials":543,"cells":544},13,{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":562,"PHASE4":564,"NA":584},{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":99},[551],{"nctId":552,"briefTitle":553,"status":151,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":561},"NCT03983720","Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?",[88],"2021-06-16","2021-07-31","2020-01-21",67,[560],"Sclerosis, Multiple",[64],{"trials":563,"activeCount":99},[],{"trials":565,"activeCount":99},[566,576],{"nctId":567,"briefTitle":568,"status":151,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT04470453","Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug",[90],"2024-04-04","2020-10-08",16,[574],"Rheumatoid Arthritis",[64],{"nctId":577,"briefTitle":578,"status":579,"phases":580,"primaryCompletion":436,"completion":436,"start":581,"enrollment":187,"conditions":582,"interventions":583},"NCT03445871","Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate","COMPLETED",[90],"2018-07-02",[574],[64],{"trials":585,"activeCount":411,"soonestReadout":63},[586,595,606,615,625,634,641,651,663,671],{"nctId":587,"briefTitle":588,"status":579,"phases":589,"primaryCompletion":590,"completion":590,"start":591,"enrollment":26,"conditions":592,"interventions":594},"NCT02862353","Thrombocytopenia Drug Immune Validation of New Biological Test Diagnostic",[],"2021-03-15","2017-10-25",[593],"Thrombocytopenia",[69],{"nctId":596,"briefTitle":597,"status":579,"phases":598,"primaryCompletion":599,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":605},"NCT03974230","Analysis of the Genotype\u002FPhenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France.",[],"2020-11-10","2021-12-14","2019-08-01",208,[604],"Fuchs Endothelial Corneal Dystrophy",[69],{"nctId":607,"briefTitle":608,"status":579,"phases":609,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":614},"NCT02526966","Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy",[91],"2014-06-30","2012-03",68,[427],[69],{"nctId":616,"briefTitle":617,"status":151,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":472,"conditions":622,"interventions":624},"NCT06257290","The Role of Platelet TLRs in Platelet Activation During VTE",[],"2025-04-09","2025-10-10","2023-10-11",[623],"Venous Thromboembolism",[69,69],{"nctId":626,"briefTitle":627,"status":124,"phases":628,"primaryCompletion":337,"completion":337,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT04657835","Multiparametric MRI Assessment of Atrial Heart Disease as a Predictor of Atrial Fibrillation After Myocardial Revascularization Surgery",[91],"2026-05-01",100,[632],"Postoperative Atrial Fibrillation",[64],{"nctId":61,"briefTitle":62,"status":111,"phases":635,"primaryCompletion":63,"completion":63,"start":636,"enrollment":637,"conditions":638,"interventions":640},[],"2020-04-01",400,[639],"Adenocarcinoma",[64],{"nctId":642,"briefTitle":643,"status":579,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT04025138","Fatigability Compared Men and Women Induced According to the Distance Traveled on an Ultra-marathon in the Mountains",[91],"2019-09-01","2019-07-02",75,[649],"Ultra-marathon Runners",[64,79],{"nctId":652,"briefTitle":653,"status":151,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":661},"NCT03172195","Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up",[91],"2024-03-13","2024-05-16","2017-10-11",80,[660],"Colitis, Ulcerative",[662,69],"biopsies",{"nctId":66,"briefTitle":67,"status":111,"phases":664,"primaryCompletion":68,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":670},[],"2027-05","2022-11-09",120,[669],"Chronic Thromboembolic Pulmonary Hypertension",[69],{"nctId":672,"briefTitle":673,"status":674,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":187,"conditions":678,"interventions":681},"NCT05807555","Longitudinal Evolution of Biomarkers of Dysautonomia and Inflammation During Sepsis in Children","UNKNOWN",[],"2025-01-01","2023-03-29",[679,680],"Sepsis","Autonomic Nervous System",[64],{"intervention":59,"totalTrials":683,"cells":684},5,{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[691],{"nctId":692,"briefTitle":693,"status":579,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT03182166","Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization",[88],"2021-06-25","2021-12-15","2017-11-21",51,[700],"Ulcerative Colitis",[702,59],"Golimumab",{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":164,"soonestReadout":58},[709,721,733,741],{"nctId":710,"briefTitle":711,"status":579,"phases":712,"primaryCompletion":713,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":720},"NCT03549546","Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.",[91],"2019-02-06","2019-02-12","2018-06-14",31,[718,719],"Lung Cancer","Surgery",[59],{"nctId":722,"briefTitle":723,"status":579,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":730},"NCT03643328","Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients",[91],"2020-12-07","2017-12-14",50,[729],"Staphylococcus Aureus",[731,732],"blood samples","nasal swabs",{"nctId":734,"briefTitle":735,"status":579,"phases":736,"primaryCompletion":737,"completion":737,"start":738,"enrollment":647,"conditions":739,"interventions":740},"NCT04842084","Normal Values of Parameters of Thrombin Generation in Function of Different Tissue Factor Concentrations",[],"2023-03-30","2021-04-23",[23],[59],{"nctId":56,"briefTitle":57,"status":111,"phases":742,"primaryCompletion":58,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},[91],"2026-04","2019-07-17",196,[747],"Cytomegalovirus Infections",[59],{"intervention":750,"totalTrials":95,"cells":751},"Apixaban",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":774,"NA":776},{"trials":753,"activeCount":99},[],{"trials":755,"activeCount":99},[],{"trials":757,"activeCount":99},[],{"trials":759,"activeCount":99},[760],{"nctId":761,"briefTitle":762,"status":151,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":770},"NCT02664155","Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants",[89],"2021-11-30","2022-05-30","2016-10-19",203,[769],"Renal Insufficiency",[750,771,772,773],"Rivaroxaban","Heparin","VKA",{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":164,"soonestReadout":782},[778],{"nctId":779,"briefTitle":780,"status":111,"phases":781,"primaryCompletion":782,"completion":184,"start":783,"enrollment":784,"conditions":785,"interventions":788},"NCT06474182","Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma",[91],"2027-03","2025-09-15",32,[786,787],"Multiple Myeloma","Total Knee Replacement",[750],{"intervention":79,"totalTrials":95,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":799,"NA":801},{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":99},[],{"trials":798,"activeCount":99},[],{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":164,"soonestReadout":78},[803,809],{"nctId":76,"briefTitle":77,"status":111,"phases":804,"primaryCompletion":78,"completion":78,"start":805,"enrollment":630,"conditions":806,"interventions":808},[],"2020-01-29",[807],"Clear Cell Renal Cell Carcinoma",[79],{"nctId":642,"briefTitle":643,"status":579,"phases":810,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":811,"interventions":812},[91],[649],[64,79],{"intervention":814,"totalTrials":164,"cells":815},"Blood samples for PK",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":824,"NA":826},{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":99},[],{"trials":823,"activeCount":99},[],{"trials":825,"activeCount":99},[],{"trials":827,"activeCount":164,"soonestReadout":114},[828],{"nctId":829,"briefTitle":830,"status":124,"phases":831,"primaryCompletion":114,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":837},"NCT07425600","Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass",[],"2028-11-07","2026-11-01",150,[836],"Fibrinogen Deficiency in Complex Cardiac Surgery",[814],{"intervention":839,"totalTrials":164,"cells":840},"Thrombin Generation Assay",{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":99},[],{"trials":852,"activeCount":164,"soonestReadout":857},[853],{"nctId":854,"briefTitle":855,"status":111,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":864},"NCT06386107","Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis",[91],"2027-07","2028-07","2025-09-02",212,[21,862,863],"Pulmonary Embolism","Thrombosis",[839],{"intervention":74,"totalTrials":164,"cells":866},{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":868,"activeCount":99},[],{"trials":870,"activeCount":99},[],{"trials":872,"activeCount":99},[],{"trials":874,"activeCount":99},[],{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":164,"soonestReadout":73},[879],{"nctId":71,"briefTitle":72,"status":111,"phases":880,"primaryCompletion":73,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":886},[],"2026-09-01","2024-08-08",500,[885],"Corneal Dystrophies",[74],{"intervention":39,"totalTrials":164,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[],{"trials":900,"activeCount":164,"soonestReadout":38},[901],{"nctId":36,"briefTitle":37,"status":111,"phases":902,"primaryCompletion":38,"completion":38,"start":903,"enrollment":904,"conditions":905,"interventions":907},[91],"2020-06-02",480,[906],"Hemophilia",[39],{"intervention":909,"totalTrials":164,"cells":910},"ceftazidime",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"trials":918,"activeCount":99},[],{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":164,"soonestReadout":927},[923],{"nctId":924,"briefTitle":925,"status":124,"phases":926,"primaryCompletion":927,"completion":927,"start":58,"enrollment":928,"conditions":929,"interventions":933},"NCT07085624","Early Optimization of Ceftazidime Regimen in Critical Care",[91],"2026-11",128,[930,679,931,932],"Infection in ICU","Septic Shock","Pseudomonas Aeruginosa Infection",[909,934],"plasma ceftazidime dosage",{"intervention":934,"totalTrials":164,"cells":936},{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":164,"soonestReadout":927},[949],{"nctId":924,"briefTitle":925,"status":124,"phases":950,"primaryCompletion":927,"completion":927,"start":58,"enrollment":928,"conditions":951,"interventions":952},[91],[930,679,931,932],[909,934],{"intervention":954,"totalTrials":164,"cells":955},"Blood collection before antiplatelet treatment",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"trials":961,"activeCount":99},[],{"trials":963,"activeCount":99},[],{"trials":965,"activeCount":99},[],{"trials":967,"activeCount":164,"soonestReadout":972},[968],{"nctId":969,"briefTitle":970,"status":111,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":727,"conditions":974,"interventions":976},"NCT05004233","Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent",[91],"2027-06","2024-12-13",[975],"Ischemic Stroke",[954,977],"Blood collection after antiplatelet treatment",{"intervention":977,"totalTrials":164,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":164,"soonestReadout":972},[992],{"nctId":969,"briefTitle":970,"status":111,"phases":993,"primaryCompletion":972,"completion":972,"start":973,"enrollment":727,"conditions":994,"interventions":995},[91],[975],[954,977],{"intervention":49,"totalTrials":164,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":164,"soonestReadout":48},[1010],{"nctId":46,"briefTitle":47,"status":111,"phases":1011,"primaryCompletion":48,"completion":48,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1016},[],"2024-09-02",405,[1015],"Bacteria Infection Mechanism",[49,1017,1018],"Antibiotic treatment","Intracellular reservoir test",{"intervention":1017,"totalTrials":164,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":99},[],{"trials":1030,"activeCount":99},[],{"trials":1032,"activeCount":164,"soonestReadout":48},[1033],{"nctId":46,"briefTitle":47,"status":111,"phases":1034,"primaryCompletion":48,"completion":48,"start":1012,"enrollment":1013,"conditions":1035,"interventions":1036},[],[1015],[49,1017,1018],{"intervention":1018,"totalTrials":164,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1040,"activeCount":99},[],{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":99},[],{"trials":1048,"activeCount":99},[],{"trials":1050,"activeCount":164,"soonestReadout":48},[1051],{"nctId":46,"briefTitle":47,"status":111,"phases":1052,"primaryCompletion":48,"completion":48,"start":1012,"enrollment":1013,"conditions":1053,"interventions":1054},[],[1015],[49,1017,1018],{"intervention":1056,"totalTrials":95,"cells":1057},"iohexol",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1090},{"trials":1059,"activeCount":99},[],{"trials":1061,"activeCount":99},[1062],{"nctId":1063,"briefTitle":1064,"status":674,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1071},"NCT05136963","Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance",[87],"2025-04","2024-06",48,[1070],"Kidney Function Test",[1072,1073],"Iohexol","pharmacokinetics",{"trials":1075,"activeCount":99},[],{"trials":1077,"activeCount":99},[],{"trials":1079,"activeCount":99},[1080],{"nctId":1081,"briefTitle":1082,"status":579,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT02522338","Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance",[90],"2013-12","2011-02",300,[1088],"HIV",[1056],{"trials":1091,"activeCount":99},[],{"intervention":1093,"totalTrials":164,"cells":1094},"mycophénolate acid",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1115},{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":99},[],{"trials":1102,"activeCount":99},[],{"trials":1104,"activeCount":99},[1105],{"nctId":1106,"briefTitle":1107,"status":579,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT00941824","Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study",[90],"2010-03","2009-02",15,[1113],"Kidney Transplantation",[1093],{"trials":1116,"activeCount":99},[],{"intervention":1118,"totalTrials":164,"cells":1119},"Secukinumab",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1142},{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"trials":1125,"activeCount":99},[],{"trials":1127,"activeCount":99},[],{"trials":1129,"activeCount":99},[1130],{"nctId":1131,"briefTitle":1132,"status":579,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1086,"conditions":1137,"interventions":1139},"NCT03445845","Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis",[90],"2024-09-21","2024-10-01","2018-12-14",[1138],"Axial Spondyloarthritis",[1118,1140,1141],"TNF blocker","blood specimen",{"trials":1143,"activeCount":99},[],{"intervention":1140,"totalTrials":164,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1160},{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[1156],{"nctId":1131,"briefTitle":1132,"status":579,"phases":1157,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1086,"conditions":1158,"interventions":1159},[90],[1138],[1118,1140,1141],{"trials":1161,"activeCount":99},[],{"intervention":1141,"totalTrials":164,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1178},{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[],{"trials":1169,"activeCount":99},[],{"trials":1171,"activeCount":99},[],{"trials":1173,"activeCount":99},[1174],{"nctId":1131,"briefTitle":1132,"status":579,"phases":1175,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1086,"conditions":1176,"interventions":1177},[90],[1138],[1118,1140,1141],{"trials":1179,"activeCount":99},[],{"intervention":1181,"totalTrials":164,"cells":1182},"Active comparator : Tranexamic Acid",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1191,"NA":1203},{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[1193],{"nctId":1194,"briefTitle":1195,"status":579,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1202},"NCT02252497","Tranexamic Acid in Total Hip Arthroplasty.",[90],"2016-01","2014-04",168,[1201],"Hip Arthroplasty",[1181],{"trials":1204,"activeCount":99},[],{"intervention":1206,"totalTrials":164,"cells":1207},"COVID-19 Vaccine Janssen",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1228},{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":99},[],{"trials":1217,"activeCount":99},[1218],{"nctId":1219,"briefTitle":1220,"status":151,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1227},"NCT05037266","Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen",[90],"2022-02-14","2024-01-29","2021-09-20",27,[23],[1206],{"trials":1229,"activeCount":99},[],{"intervention":1231,"totalTrials":164,"cells":1232},"period with drug (trade name) then period with generic",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1253},{"trials":1234,"activeCount":99},[],{"trials":1236,"activeCount":99},[],{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[1243],{"nctId":1244,"briefTitle":1245,"status":579,"phases":1246,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":727,"conditions":1249,"interventions":1251},"NCT02853045","Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients",[90],"2021-03-10","2015-06-11",[1250],"Hypertension",[1231,1252],"period with generic then period with drug",{"trials":1254,"activeCount":99},[],{"intervention":1252,"totalTrials":164,"cells":1256},{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1263,"PHASE4":1265,"NA":1271},{"trials":1258,"activeCount":99},[],{"trials":1260,"activeCount":99},[],{"trials":1262,"activeCount":99},[],{"trials":1264,"activeCount":99},[],{"trials":1266,"activeCount":99},[1267],{"nctId":1244,"briefTitle":1245,"status":579,"phases":1268,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":727,"conditions":1269,"interventions":1270},[90],[1250],[1231,1252],{"trials":1272,"activeCount":99},[],{"intervention":1274,"totalTrials":164,"cells":1275},"ATG-F",{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1299},{"trials":1277,"activeCount":99},[],{"trials":1279,"activeCount":99},[],{"trials":1281,"activeCount":99},[],{"trials":1283,"activeCount":99},[],{"trials":1285,"activeCount":99},[1286],{"nctId":1287,"briefTitle":1288,"status":151,"phases":1289,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1297},"NCT02523768","Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment",[90],"2020-01-24","2020-02-24","2011-01-08",117,[1295,1296],"Glomerulonephritis","IgAN",[1274,1298],"Simulect",{"trials":1300,"activeCount":99},[],{"intervention":1298,"totalTrials":164,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1309,"PHASE4":1311,"NA":1317},{"trials":1304,"activeCount":99},[],{"trials":1306,"activeCount":99},[],{"trials":1308,"activeCount":99},[],{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":99},[1313],{"nctId":1287,"briefTitle":1288,"status":151,"phases":1314,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":1315,"interventions":1316},[90],[1295,1296],[1274,1298],{"trials":1318,"activeCount":99},[],{"intervention":1320,"totalTrials":164,"cells":1321},"Lovenox 40 MG in 0.4 mL Prefilled Syringe",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1341},{"trials":1323,"activeCount":99},[],{"trials":1325,"activeCount":99},[],{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"trials":1331,"activeCount":99},[1332],{"nctId":1333,"briefTitle":1334,"status":1335,"phases":1336,"primaryCompletion":1337,"completion":1337,"start":1338,"enrollment":99,"conditions":1339,"interventions":1340},"NCT04520620","Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention","WITHDRAWN",[90],"2020-07-10","2020-05-02",[439],[1320],{"trials":1342,"activeCount":99},[],{"intervention":1344,"totalTrials":164,"cells":1345},"fondaparinux 1.5 mg\u002Fday",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1366},{"trials":1347,"activeCount":99},[],{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[1356],{"nctId":1357,"briefTitle":1358,"status":579,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT00555438","Prospective, Multicentre, Open-label Study Evaluating 1.5 mg\u002FDay of Fondaparinux.",[90],"2008-10","2007-06",451,[1364],"Major Orthopaedic Surgery and Renal Impairment",[1344],{"trials":1367,"activeCount":99},[],{"intervention":1369,"totalTrials":164,"cells":1370},"Antidepressants",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1392},{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[1381],{"nctId":1382,"briefTitle":1383,"status":579,"phases":1384,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":698,"conditions":1388,"interventions":1390},"NCT02359513","Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.",[90],"2021-11-12","2022-03-11","2015-11-09",[1389],"Bulimia Nervosa",[1369,1391],"Positron Emission Tomography",{"trials":1393,"activeCount":99},[],{"intervention":1391,"totalTrials":164,"cells":1395},{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1410},{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[1406],{"nctId":1382,"briefTitle":1383,"status":579,"phases":1407,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":698,"conditions":1408,"interventions":1409},[90],[1389],[1369,1391],{"trials":1411,"activeCount":99},[],{"intervention":1413,"totalTrials":164,"cells":1414},"alcoholic povidone iodine",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1437},{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":99},[],{"trials":1424,"activeCount":99},[1425],{"nctId":1426,"briefTitle":1427,"status":579,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1435},"NCT01841242","Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation",[90],"2021-01-31","2013-04-23",2272,[1433,1434],"Heart Failure","Arrhythmia",[1413,1436],"alcoholic chlorhexidine",{"trials":1438,"activeCount":99},[],{"intervention":1436,"totalTrials":164,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1449,"NA":1455},{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[1451],{"nctId":1426,"briefTitle":1427,"status":579,"phases":1452,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1453,"interventions":1454},[90],[1433,1434],[1413,1436],{"trials":1456,"activeCount":99},[],{"intervention":1458,"totalTrials":164,"cells":1459},"Cohort HIVOL, patients infected by HIV",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1479},{"trials":1461,"activeCount":99},[],{"trials":1463,"activeCount":99},[],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[1470],{"nctId":1471,"briefTitle":1472,"status":579,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1478},"NCT02667678","5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients",[90],"2018-09-30","2016-02-08",173,[1088],[1458],{"trials":1480,"activeCount":99},[],{"intervention":1482,"totalTrials":164,"cells":1483},"etomidate",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1502},{"trials":1485,"activeCount":99},[],{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[1494],{"nctId":1495,"briefTitle":1496,"status":579,"phases":1497,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":630,"conditions":1498,"interventions":1500},"NCT00451776","Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC",[90],[1499],"Cardiac Surgery",[1482,1501],"propofol",{"trials":1503,"activeCount":99},[],{"intervention":1501,"totalTrials":164,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1520},{"trials":1507,"activeCount":99},[],{"trials":1509,"activeCount":99},[],{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":99},[1516],{"nctId":1495,"briefTitle":1496,"status":579,"phases":1517,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":630,"conditions":1518,"interventions":1519},[90],[1499],[1482,1501],{"trials":1521,"activeCount":99},[],{"intervention":1523,"totalTrials":164,"cells":1524},"COVID-19 vaccine Pfizer",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1533,"NA":1547},{"trials":1526,"activeCount":99},[],{"trials":1528,"activeCount":99},[],{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[1535],{"nctId":1536,"briefTitle":1537,"status":579,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1543,"interventions":1545},"NCT05047718","Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19",[90],"2022-08-29","2023-02-28","2021-10-05",54,[1544],"Covid19",[1523,1523,1546,1546,1546],"COVID-19 mRNA Vaccine Moderna",{"trials":1548,"activeCount":99},[],{"intervention":1546,"totalTrials":164,"cells":1550},{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1559,"NA":1565},{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[1561],{"nctId":1536,"briefTitle":1537,"status":579,"phases":1562,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1563,"interventions":1564},[90],[1544],[1523,1523,1546,1546,1546],{"trials":1566,"activeCount":99},[],{"intervention":1568,"totalTrials":164,"cells":1569},"Decolonization",{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1590},{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[1580],{"nctId":1581,"briefTitle":1582,"status":151,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1589},"NCT02945722","Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers",[90],"2024-10-26","2018-02-23",434,[1588],"Hemodialysis Patients",[1568],{"trials":1591,"activeCount":99},[],{"intervention":771,"totalTrials":1593,"cells":1594},4,{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1620,"PHASE3":1622,"PHASE4":1640,"NA":1642},{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[1599,1610],{"nctId":1600,"briefTitle":1601,"status":579,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1608},"NCT04767776","Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.",[87],"2022-09-26","2022-11-04","2022-01-03",12,[15],[771,1609],"Activated charcoal",{"nctId":1611,"briefTitle":1612,"status":579,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1197,"enrollment":1606,"conditions":1616,"interventions":1617},"NCT02657512","Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects",[87],"2016-02","2016-04",[15],[1618,1619],"rivaroxaban","rivaroxaban and activated charcoal",{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[1624,1636],{"nctId":1625,"briefTitle":1626,"status":151,"phases":1627,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":1632,"interventions":1634},"NCT02401594","PROphylaxis in NOn Major Orthopaedic Surgery",[89],"2018-04-11","2018-04-16","2015-12-08",3608,[1633],"Non-major Orthopaedic Surgery",[771,1635],"Enoxaparin",{"nctId":761,"briefTitle":762,"status":151,"phases":1637,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":1638,"interventions":1639},[89],[769],[750,771,772,773],{"trials":1641,"activeCount":99},[],{"trials":1643,"activeCount":99},[],{"intervention":1645,"totalTrials":95,"cells":1646},"Tranexamic acid",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1664,"PHASE4":1676,"NA":1678},{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[1653],{"nctId":1654,"briefTitle":1655,"status":579,"phases":1656,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":1660,"conditions":1661,"interventions":1663},"NCT03801122","Evolution of Thromboelastography During Tranexamic Acid Treatment",[88],"2022-03-09","2022-07-11","2019-03-05",18,[1662],"Hematological Malignancies Treated With Intensive Chemotherapy",[1645],{"trials":1665,"activeCount":99},[1666],{"nctId":1667,"briefTitle":1668,"status":579,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1675},"NCT00327106","Tranexamic Acid in HIp Fracture Surgery (THIF Study)",[89],"2007-02","2005-04",110,[1674],"Hip Fracture",[1645],{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"intervention":1635,"totalTrials":95,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1705,"NA":1707},{"trials":1683,"activeCount":99},[],{"trials":1685,"activeCount":99},[],{"trials":1687,"activeCount":99},[],{"trials":1689,"activeCount":99},[1690,1701],{"nctId":1691,"briefTitle":1692,"status":579,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1700},"NCT02672566","Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction",[89],"2019-09-05","2020-01-22","2016-07-22",82,[1699],"Fetal Growth Retardation",[1635],{"nctId":1625,"briefTitle":1626,"status":151,"phases":1702,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":1703,"interventions":1704},[89],[1633],[771,1635],{"trials":1706,"activeCount":99},[],{"trials":1708,"activeCount":99},[],{"intervention":1710,"totalTrials":164,"cells":1711},"Radium bromatum pills",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1733,"NA":1735},{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[],{"trials":1719,"activeCount":99},[1720],{"nctId":1721,"briefTitle":1722,"status":579,"phases":1723,"primaryCompletion":1724,"completion":1725,"start":1726,"enrollment":1727,"conditions":1728,"interventions":1730},"NCT03753776","Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women",[89],"2024-01-05","2024-04-05","2019-07-15",232,[1729],"Breast Cancer",[1710,1731,1732],"Radium bromatum\u002FApis mellifica\u002FBelladonna placebo pills","Radium bromatum\u002FApis mellifica\u002FBelladonna pills",{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[],{"intervention":1731,"totalTrials":164,"cells":1738},{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1745,"PHASE4":1751,"NA":1753},{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[1747],{"nctId":1721,"briefTitle":1722,"status":579,"phases":1748,"primaryCompletion":1724,"completion":1725,"start":1726,"enrollment":1727,"conditions":1749,"interventions":1750},[89],[1729],[1710,1731,1732],{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[],{"intervention":1732,"totalTrials":164,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1769,"NA":1771},{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":99},[],{"trials":1762,"activeCount":99},[],{"trials":1764,"activeCount":99},[1765],{"nctId":1721,"briefTitle":1722,"status":579,"phases":1766,"primaryCompletion":1724,"completion":1725,"start":1726,"enrollment":1727,"conditions":1767,"interventions":1768},[89],[1729],[1710,1731,1732],{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":99},[],{"intervention":1774,"totalTrials":164,"cells":1775},"GEMCIS",{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1782,"PHASE4":1796,"NA":1798},{"trials":1777,"activeCount":99},[],{"trials":1779,"activeCount":99},[],{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[1784],{"nctId":1785,"briefTitle":1786,"status":579,"phases":1787,"primaryCompletion":1788,"completion":1789,"start":1790,"enrollment":1791,"conditions":1792,"interventions":1794},"NCT02591030","Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours",[88,89],"2018-06-27","2020-01-16","2015-12-15",191,[1793],"Bile Duct Cancer",[1774,1795],"mFolfirinox",{"trials":1797,"activeCount":99},[],{"trials":1799,"activeCount":99},[],{"intervention":1795,"totalTrials":164,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1808,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":99},[],{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[1810],{"nctId":1785,"briefTitle":1786,"status":579,"phases":1811,"primaryCompletion":1788,"completion":1789,"start":1790,"enrollment":1791,"conditions":1812,"interventions":1813},[88,89],[1793],[1774,1795],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"intervention":1819,"totalTrials":164,"cells":1820},"isotope",{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1841,"NA":1843},{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[1829],{"nctId":1830,"briefTitle":1831,"status":579,"phases":1832,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":1836,"conditions":1837,"interventions":1839},"NCT02279108","Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer",[89],"2016-05","2016-07","2014-11",99,[1838],"Breast Neoplasms",[1840,1819],"indocyanine green",{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"intervention":1846,"totalTrials":164,"cells":1847},"Immunoglobulin perfusion",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1865,"NA":1867},{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[1856],{"nctId":1857,"briefTitle":1858,"status":579,"phases":1859,"primaryCompletion":1084,"completion":1084,"start":1860,"enrollment":511,"conditions":1861,"interventions":1863},"NCT01349270","Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg",[89],"2004-06",[1862],"Demyelinating Polyneuropathy",[1846,1864],"Prednisone",{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[],{"intervention":1864,"totalTrials":164,"cells":1870},{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1877,"PHASE4":1883,"NA":1885},{"trials":1872,"activeCount":99},[],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[1879],{"nctId":1857,"briefTitle":1858,"status":579,"phases":1880,"primaryCompletion":1084,"completion":1084,"start":1860,"enrollment":511,"conditions":1881,"interventions":1882},[89],[1862],[1846,1864],{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"intervention":1888,"totalTrials":164,"cells":1889},"Propofol induced sedation",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1908,"NA":1910},{"trials":1891,"activeCount":99},[],{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":99},[],{"trials":1897,"activeCount":99},[1898],{"nctId":1899,"briefTitle":1900,"status":579,"phases":1901,"primaryCompletion":1902,"completion":1902,"start":1903,"enrollment":1904,"conditions":1905,"interventions":1907},"NCT02046720","The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation",[89],"2013-11","2010-06",70,[1906],"Anesthesia",[1888],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"intervention":1913,"totalTrials":164,"cells":1914},"Valganciclovir",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1934,"NA":1936},{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[],{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[1923],{"nctId":1924,"briefTitle":1925,"status":151,"phases":1926,"primaryCompletion":1927,"completion":1928,"start":1929,"enrollment":1930,"conditions":1931,"interventions":1933},"NCT04064697","Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy",[89],"2023-11-23","2024-02-08","2021-04-22",6,[1932],"Ulcerative Colitis, Unspecified",[1913],{"trials":1935,"activeCount":99},[],{"trials":1937,"activeCount":99},[],{"intervention":1939,"totalTrials":164,"cells":1940},"UFH Early group",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1960,"NA":1962},{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[1949],{"nctId":1950,"briefTitle":1951,"status":151,"phases":1952,"primaryCompletion":1953,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1958},"NCT02091479","Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage",[89],"2015-06","2013-01",14,[1957],"Major hæmorrhage",[1939,1959],"UFH Late group",{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"intervention":1959,"totalTrials":164,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[],{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[1974],{"nctId":1950,"briefTitle":1951,"status":151,"phases":1975,"primaryCompletion":1953,"completion":1953,"start":1954,"enrollment":1955,"conditions":1976,"interventions":1977},[89],[1957],[1939,1959],{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"intervention":452,"totalTrials":164,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1990,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[1992],{"nctId":442,"briefTitle":443,"status":151,"phases":1993,"primaryCompletion":445,"completion":446,"start":447,"enrollment":448,"conditions":1994,"interventions":1995},[89],[450],[410,452],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"intervention":2001,"totalTrials":164,"cells":2002},"St Thomas",{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2009,"PHASE4":2020,"NA":2022},{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[],{"trials":2010,"activeCount":99},[2011],{"nctId":2012,"briefTitle":2013,"status":579,"phases":2014,"primaryCompletion":611,"completion":611,"start":1903,"enrollment":2015,"conditions":2016,"interventions":2018},"NCT01401140","Comparing the Protective Effects of Two Cardioplegic Solutions, on Cardiac Metabolism, as Assessed Using Microdialysis",[89],29,[2017],"Coronary Artery Stenosis",[2001,2019],"Custodiol",{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"intervention":2019,"totalTrials":164,"cells":2025},{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2038,"NA":2040},{"trials":2027,"activeCount":99},[],{"trials":2029,"activeCount":99},[],{"trials":2031,"activeCount":99},[],{"trials":2033,"activeCount":99},[2034],{"nctId":2012,"briefTitle":2013,"status":579,"phases":2035,"primaryCompletion":611,"completion":611,"start":1903,"enrollment":2015,"conditions":2036,"interventions":2037},[89],[2017],[2001,2019],{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[],{"intervention":2043,"totalTrials":164,"cells":2044},"Glucose sucking",{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2051,"PHASE4":2064,"NA":2066},{"trials":2046,"activeCount":99},[],{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[2053],{"nctId":2054,"briefTitle":2055,"status":579,"phases":2056,"primaryCompletion":2057,"completion":2057,"start":2058,"enrollment":251,"conditions":2059,"interventions":2062},"NCT02374281","Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking",[89],"2015-04","2014-12",[2060,2061],"Newborn","Neonatal Screening",[2043,2063],"Water sucking",{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"intervention":2063,"totalTrials":164,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[2078],{"nctId":2054,"briefTitle":2055,"status":579,"phases":2079,"primaryCompletion":2057,"completion":2057,"start":2058,"enrollment":251,"conditions":2080,"interventions":2081},[89],[2060,2061],[2043,2063],{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[],{"intervention":2087,"totalTrials":164,"cells":2088},"Methylprednisolone + prednisolone",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2105,"NA":2107},{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[],{"trials":2096,"activeCount":99},[2097],{"nctId":2098,"briefTitle":2099,"status":1335,"phases":2100,"primaryCompletion":423,"completion":423,"start":2101,"enrollment":99,"conditions":2102,"interventions":2104},"NCT03249844","Paediatric Arteriopathy Steroid Aspirin Project",[89],"2022-09-01",[2103],"Arterial Ischemic Stroke",[2087],{"trials":2106,"activeCount":99},[],{"trials":2108,"activeCount":99},[],{"intervention":2110,"totalTrials":164,"cells":2111},"chirocaine",{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2131,"NA":2133},{"trials":2113,"activeCount":99},[],{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[2120],{"nctId":2121,"briefTitle":2122,"status":579,"phases":2123,"primaryCompletion":2124,"completion":2124,"start":2125,"enrollment":2126,"conditions":2127,"interventions":2129},"NCT00621907","Study : LEVOBUPIVACAINE Versus Placebo",[89],"2009-05","2008-03",140,[2128],"Pain",[2110,2130],"sodium chloride",{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"intervention":2130,"totalTrials":164,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2149,"NA":2151},{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[2145],{"nctId":2121,"briefTitle":2122,"status":579,"phases":2146,"primaryCompletion":2124,"completion":2124,"start":2125,"enrollment":2126,"conditions":2147,"interventions":2148},[89],[2128],[2110,2130],{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"intervention":2154,"totalTrials":164,"cells":2155},"5-ASA",{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2162,"PHASE4":2174,"NA":2176},{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[2164],{"nctId":2165,"briefTitle":2166,"status":579,"phases":2167,"primaryCompletion":2168,"completion":2168,"start":2169,"enrollment":2170,"conditions":2171,"interventions":2172},"NCT02665845","Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).",[89],"2021-05-11","2016-06-13",160,[700],[2154,2173],"Corticosteroids",{"trials":2175,"activeCount":99},[],{"trials":2177,"activeCount":99},[],{"intervention":2173,"totalTrials":164,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2192,"NA":2194},{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[2188],{"nctId":2165,"briefTitle":2166,"status":579,"phases":2189,"primaryCompletion":2168,"completion":2168,"start":2169,"enrollment":2170,"conditions":2190,"interventions":2191},[89],[700],[2154,2173],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"intervention":772,"totalTrials":164,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2210,"NA":2212},{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[],{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[2206],{"nctId":761,"briefTitle":762,"status":151,"phases":2207,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":2208,"interventions":2209},[89],[769],[750,771,772,773],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[],{"intervention":773,"totalTrials":164,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2222,"PHASE4":2228,"NA":2230},{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":99},[2224],{"nctId":761,"briefTitle":762,"status":151,"phases":2225,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":2226,"interventions":2227},[89],[769],[750,771,772,773],{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[],{"intervention":2233,"totalTrials":164,"cells":2234},"Ramipril",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2254,"NA":2256},{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[2243],{"nctId":2244,"briefTitle":2245,"status":151,"phases":2246,"primaryCompletion":2247,"completion":2247,"start":2248,"enrollment":2249,"conditions":2250,"interventions":2253},"NCT00736294","Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter",[89],"2015-03","2008-07",198,[2251,2252],"Atrial Fibrillation","Atrial Flutter",[2233],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"intervention":2259,"totalTrials":164,"cells":2260},"Tinzaparin",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[2267],{"nctId":2268,"briefTitle":2269,"status":579,"phases":2270,"primaryCompletion":2271,"completion":2271,"start":2272,"enrollment":2273,"conditions":2274,"interventions":2276},"NCT02260414","Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer",[88],"2017-05-09","2015-04-14",19,[2275,786],"Lymphoma",[2259],{"trials":2278,"activeCount":99},[],{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[],{"intervention":2284,"totalTrials":164,"cells":2285},"Group 1: perfusion of 300 mg Exacyl",{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2290,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[2292],{"nctId":2293,"briefTitle":2294,"status":579,"phases":2295,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":2299,"conditions":2300,"interventions":2302},"NCT03822793","A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty",[88],"2025-04-21","2025-07-11","2023-12-07",170,[2301],"Arthropathy of Hip",[2284,2303,2304,2305],"Group 2: perfusion of 500 mg Exacyl","Group 3: perfusion of 1000 mg Exacyl","Group 4: perfusion of 3000 mg Exacyl",{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[],{"intervention":2303,"totalTrials":164,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2324,"PHASE4":2326,"NA":2328},{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[2320],{"nctId":2293,"briefTitle":2294,"status":579,"phases":2321,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":2299,"conditions":2322,"interventions":2323},[88],[2301],[2284,2303,2304,2305],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"intervention":2304,"totalTrials":164,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[2338],{"nctId":2293,"briefTitle":2294,"status":579,"phases":2339,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":2299,"conditions":2340,"interventions":2341},[88],[2301],[2284,2303,2304,2305],{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"trials":2347,"activeCount":99},[],{"intervention":2305,"totalTrials":164,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"trials":2355,"activeCount":99},[2356],{"nctId":2293,"briefTitle":2294,"status":579,"phases":2357,"primaryCompletion":2296,"completion":2297,"start":2298,"enrollment":2299,"conditions":2358,"interventions":2359},[88],[2301],[2284,2303,2304,2305],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"trials":2365,"activeCount":99},[],{"intervention":2367,"totalTrials":164,"cells":2368},"Fibrinogen Concentrate Human",{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[2375],{"nctId":2376,"briefTitle":2377,"status":151,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":164,"conditions":2382,"interventions":2386},"NCT05091684","Administration of Fibrinogen Concentrate for Refractory Bleeding",[88],"2023-05-25","2023-06-27","2022-02-10",[2383,2384,2385],"Hematological Patients","Bleeding","Platelet Refractoriness",[2367],{"trials":2388,"activeCount":99},[],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":99},[],{"intervention":702,"totalTrials":164,"cells":2394},{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2405,"PHASE4":2407,"NA":2409},{"trials":2396,"activeCount":99},[],{"trials":2398,"activeCount":99},[],{"trials":2400,"activeCount":99},[2401],{"nctId":692,"briefTitle":693,"status":579,"phases":2402,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":2403,"interventions":2404},[88],[700],[702,59],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[],{"intervention":2412,"totalTrials":164,"cells":2413},"optimal TURB",{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2415,"activeCount":99},[],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[2420],{"nctId":2421,"briefTitle":2422,"status":151,"phases":2423,"primaryCompletion":2424,"completion":2424,"start":2425,"enrollment":2426,"conditions":2427,"interventions":2429},"NCT01093066","Prospective Multicentric Evaluation of a Bladder Preservation Strategy",[88],"2020-12-31","2010-09-21",77,[2428],"Urothelial Carcinoma",[2412],{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"intervention":2437,"totalTrials":164,"cells":2438},"Prevenar 13",{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2443,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[2445],{"nctId":2446,"briefTitle":2447,"status":151,"phases":2448,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2456},"NCT02255227","Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD",[88],"2019-08-06","2022-07-06","2015-04-13",104,[2454,2455],"Infections, Pneumococcal","Bowel Diseases, Inflammatory",[2437,2457],"Pneumo 23",{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"intervention":2457,"totalTrials":164,"cells":2465},{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2467,"activeCount":99},[],{"trials":2469,"activeCount":99},[],{"trials":2471,"activeCount":99},[2472],{"nctId":2446,"briefTitle":2447,"status":151,"phases":2473,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":2474,"interventions":2475},[88],[2454,2455],[2437,2457],{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"intervention":2483,"totalTrials":164,"cells":2484},"Dexamethasone implant OZURDEX",{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[2491],{"nctId":2492,"briefTitle":2493,"status":579,"phases":2494,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":1955,"conditions":2498,"interventions":2502},"NCT02834260","Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study",[88],"2018-08-28","2019-08-08","2017-01-10",[2499,2500,2501],"Keratoconus","Fuchs' Endothelial Dystrophy","Congenital Hereditary Stromal Dystrophy of the Cornea",[2483],{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":99},[],{"intervention":2510,"totalTrials":164,"cells":2511},"Qutenza",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[2518],{"nctId":2519,"briefTitle":2520,"status":579,"phases":2521,"primaryCompletion":2522,"completion":2523,"start":2524,"enrollment":2525,"conditions":2526,"interventions":2527},"NCT03317613","Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain",[88],"2020-12-04","2021-12-20","2017-11-09",84,[25],[2510],{"trials":2529,"activeCount":99},[],{"trials":2531,"activeCount":99},[],{"trials":2533,"activeCount":99},[],{"intervention":2535,"totalTrials":164,"cells":2536},"Lidocaine",{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2554,"PHASE4":2556,"NA":2558},{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[2543],{"nctId":2544,"briefTitle":2545,"status":151,"phases":2546,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":2549,"conditions":2550,"interventions":2552},"NCT04250805","Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy",[88],"2024-01-23","2020-10-27",17,[21,2551],"Feeding Disorders",[2535,2553],"Ropivacaine",{"trials":2555,"activeCount":99},[],{"trials":2557,"activeCount":99},[],{"trials":2559,"activeCount":99},[],{"intervention":2553,"totalTrials":164,"cells":2561},{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2563,"activeCount":99},[],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[2568],{"nctId":2544,"briefTitle":2545,"status":151,"phases":2569,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":2549,"conditions":2570,"interventions":2571},[88],[21,2551],[2535,2553],{"trials":2573,"activeCount":99},[],{"trials":2575,"activeCount":99},[],{"trials":2577,"activeCount":99},[],{"intervention":2579,"totalTrials":164,"cells":2580},"Clopidogrel then fluoxetine+clopidogrel",{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2593,"PHASE3":2595,"PHASE4":2597,"NA":2599},{"trials":2582,"activeCount":99},[],{"trials":2584,"activeCount":99},[2585],{"nctId":2586,"briefTitle":2587,"status":579,"phases":2588,"primaryCompletion":2124,"completion":2124,"start":1110,"enrollment":2589,"conditions":2590,"interventions":2591},"NCT00732290","Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine",[87],10,[15],[2579,2592],"Fluoxetine+clopidogrel then clopidogrel",{"trials":2594,"activeCount":99},[],{"trials":2596,"activeCount":99},[],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"intervention":2592,"totalTrials":164,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2611,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":99},[],{"trials":2606,"activeCount":99},[2607],{"nctId":2586,"briefTitle":2587,"status":579,"phases":2608,"primaryCompletion":2124,"completion":2124,"start":1110,"enrollment":2589,"conditions":2609,"interventions":2610},[87],[15],[2579,2592],{"trials":2612,"activeCount":99},[],{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[],{"intervention":1609,"totalTrials":164,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2629,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":99},[],{"trials":2624,"activeCount":99},[2625],{"nctId":1600,"briefTitle":1601,"status":579,"phases":2626,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":2627,"interventions":2628},[87],[15],[771,1609],{"trials":2630,"activeCount":99},[],{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[],{"intervention":1619,"totalTrials":164,"cells":2638},{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2647,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[2643],{"nctId":1611,"briefTitle":1612,"status":579,"phases":2644,"primaryCompletion":1614,"completion":1615,"start":1197,"enrollment":1606,"conditions":2645,"interventions":2646},[87],[15],[1618,1619],{"trials":2648,"activeCount":99},[],{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"intervention":1073,"totalTrials":164,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2665,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[2661],{"nctId":1063,"briefTitle":1064,"status":674,"phases":2662,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":1068,"conditions":2663,"interventions":2664},[87],[1070],[1072,1073],{"trials":2666,"activeCount":99},[],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"intervention":2674,"totalTrials":164,"cells":2675},"Dabigatran",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[2680],{"nctId":2681,"briefTitle":2682,"status":579,"phases":2683,"primaryCompletion":2684,"completion":2685,"start":2686,"enrollment":1606,"conditions":2687,"interventions":2688},"NCT02524210","Effect of Inhibitors of the Proton Pump on Intestinal Transporters",[87],"2015-05","2015-12","2014-05",[15],[2674,2689,2690],"Rabeprazole and Dabigatran","Omeprazole and Dabigatran",{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[],{"trials":2696,"activeCount":99},[],{"trials":2698,"activeCount":99},[],{"intervention":2689,"totalTrials":164,"cells":2700},{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[2705],{"nctId":2681,"briefTitle":2682,"status":579,"phases":2706,"primaryCompletion":2684,"completion":2685,"start":2686,"enrollment":1606,"conditions":2707,"interventions":2708},[87],[15],[2674,2689,2690],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":99},[],{"intervention":2690,"totalTrials":164,"cells":2718},{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2727,"PHASE3":2729,"PHASE4":2731,"NA":2733},{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[2723],{"nctId":2681,"briefTitle":2682,"status":579,"phases":2724,"primaryCompletion":2684,"completion":2685,"start":2686,"enrollment":1606,"conditions":2725,"interventions":2726},[87],[15],[2674,2689,2690],{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[],{"trials":2732,"activeCount":99},[],{"trials":2734,"activeCount":99},[],{"intervention":2736,"totalTrials":164,"cells":2737},"Dabigatran then dabigatran and clarithromycin",{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2751,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2739,"activeCount":99},[],{"trials":2741,"activeCount":99},[2742],{"nctId":2743,"briefTitle":2744,"status":579,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2589,"conditions":2748,"interventions":2749},"NCT01385683","Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin",[87],"2011-12","2011-06",[15],[2736,2750],"Clarithromycin and dabigatran then dabigatran",{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[],{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[],{"intervention":2750,"totalTrials":164,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2769,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":99},[2765],{"nctId":2743,"briefTitle":2744,"status":579,"phases":2766,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2589,"conditions":2767,"interventions":2768},[87],[15],[2736,2750],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[],{"intervention":1840,"totalTrials":411,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2798,"NA":2800},{"trials":2780,"activeCount":99},[],{"trials":2782,"activeCount":99},[],{"trials":2784,"activeCount":99},[],{"trials":2786,"activeCount":99},[2787,2791],{"nctId":1830,"briefTitle":1831,"status":579,"phases":2788,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":1836,"conditions":2789,"interventions":2790},[89],[1838],[1840,1819],{"nctId":2792,"briefTitle":2793,"status":1335,"phases":2794,"primaryCompletion":1614,"completion":1614,"start":1198,"enrollment":99,"conditions":2795,"interventions":2797},"NCT02260349","Interest of Indocyanine Green in Neoplastic Prostatic Tissue",[89],[2796],"Prostatic Neoplasms",[1840],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[2802],{"nctId":2803,"briefTitle":2804,"status":579,"phases":2805,"primaryCompletion":2806,"completion":2058,"start":2807,"enrollment":2589,"conditions":2808,"interventions":2810},"NCT01982227","Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.",[],"2014-09","2013-03",[2809],"Colorectal Cancer Metastatic",[1840],{"intervention":2812,"totalTrials":95,"cells":2813},"blood test",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2820,"PHASE4":2822,"NA":2824},{"trials":2815,"activeCount":99},[],{"trials":2817,"activeCount":99},[],{"trials":2819,"activeCount":99},[],{"trials":2821,"activeCount":99},[],{"trials":2823,"activeCount":99},[],{"trials":2825,"activeCount":99},[2826,2839],{"nctId":2827,"briefTitle":2828,"status":151,"phases":2829,"primaryCompletion":2830,"completion":2831,"start":2832,"enrollment":2833,"conditions":2834,"interventions":2838},"NCT04363606","Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability",[91],"2021-08-26","2022-03-01","2020-05-27",69,[2835,2836,2837],"Chronic Fatigue Syndrome","Intensive Care Unit","Muscle",[2812],{"nctId":2840,"briefTitle":2841,"status":1335,"phases":2842,"primaryCompletion":38,"completion":1066,"start":2843,"enrollment":99,"conditions":2844,"interventions":2845},"NCT03849326","Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function",[91],"2023-12",[2835,2836,2837],[2812],{"intervention":2847,"totalTrials":164,"cells":2848},"Clopidogrel",{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2850,"activeCount":99},[],{"trials":2852,"activeCount":99},[],{"trials":2854,"activeCount":99},[],{"trials":2856,"activeCount":99},[],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[2861],{"nctId":2862,"briefTitle":2863,"status":579,"phases":2864,"primaryCompletion":2685,"completion":2685,"start":2865,"enrollment":2866,"conditions":2867,"interventions":2870},"NCT01955642","Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke",[],"2013-09",91,[2868,2869],"Brain Ischemia","Ischemic Attack",[2847],{"intervention":2872,"totalTrials":164,"cells":2873},"dosage of 17 cytokines",{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2878,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2875,"activeCount":99},[],{"trials":2877,"activeCount":99},[],{"trials":2879,"activeCount":99},[],{"trials":2881,"activeCount":99},[],{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":99},[2886],{"nctId":2887,"briefTitle":2888,"status":151,"phases":2889,"primaryCompletion":2890,"completion":2891,"start":2892,"enrollment":411,"conditions":2893,"interventions":2897},"NCT04104594","Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps",[91],"2021-07-06","2021-07-29","2020-02-05",[2894,2895,2896],"Nasal Polyps","Chronic Rhinosinusitis With Nasal Polyps","Olfaction Disorders",[2872],{"intervention":2899,"totalTrials":164,"cells":2900},"Oral anticoagulant treatment",{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2907,"PHASE4":2909,"NA":2911},{"trials":2902,"activeCount":99},[],{"trials":2904,"activeCount":99},[],{"trials":2906,"activeCount":99},[],{"trials":2908,"activeCount":99},[],{"trials":2910,"activeCount":99},[],{"trials":2912,"activeCount":99},[2913],{"nctId":2914,"briefTitle":2915,"status":579,"phases":2916,"primaryCompletion":2917,"completion":2918,"start":2919,"enrollment":767,"conditions":2920,"interventions":2922},"NCT02800941","Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension",[],"2022-09-13","2023-09-05","2017-07-05",[2921],"Pulmonary Arterial Hypertension",[2899],{"intervention":732,"totalTrials":164,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2926,"activeCount":99},[],{"trials":2928,"activeCount":99},[],{"trials":2930,"activeCount":99},[],{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[2937],{"nctId":722,"briefTitle":723,"status":579,"phases":2938,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":2939,"interventions":2940},[91],[729],[731,732],{"intervention":2942,"totalTrials":164,"cells":2943},"Retrievable Inferior Vena Cava Filters",{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[],{"trials":2949,"activeCount":99},[],{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[2956],{"nctId":2957,"briefTitle":2958,"status":579,"phases":2959,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":2962,"conditions":2963,"interventions":2965},"NCT04785313","Anatomopathological Analysis and Clinical Evolution After Radiological Removal of Retrievable Vena Cava Filters",[],"2015-04-30","2015-01-15",85,[2964],"Vena Cava Thrombosis",[2942],{"intervention":2967,"totalTrials":164,"cells":2968},"blood sampling",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2977,"NA":2979},{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[],{"trials":2974,"activeCount":99},[],{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[2981],{"nctId":2982,"briefTitle":2983,"status":1335,"phases":2984,"primaryCompletion":2985,"completion":2985,"start":2985,"enrollment":99,"conditions":2986,"interventions":2988},"NCT03736642","Study of the Microbiological Profile of Stool in Patients With Anorexia Nervosa",[],"2019-05-15",[32,2987],"Eating Disorder",[2967],{"intervention":2990,"totalTrials":164,"cells":2991},"Positron Emission Tomography using [11C]diprenorphine",{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3000,"NA":3002},{"trials":2993,"activeCount":99},[],{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[],{"trials":2999,"activeCount":99},[],{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[3004],{"nctId":3005,"briefTitle":3006,"status":579,"phases":3007,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":3012,"interventions":3015},"NCT02524301","Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study",[91],"2016-07-28","2016-07-29","2009-09",53,[3013,3014],"Body Dysmorphic Disorders","Anorexia",[2990],{"intervention":3017,"totalTrials":164,"cells":3018},"Fasting blood sample",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":99},[],{"trials":3024,"activeCount":99},[],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[3031],{"nctId":3032,"briefTitle":3033,"status":579,"phases":3034,"primaryCompletion":3035,"completion":3036,"start":3037,"enrollment":658,"conditions":3038,"interventions":3040},"NCT05955729","Effect of a Short Nap During the Night Shift of Healthcare Workers on Endothelial Function",[91],"2025-09-26","2025-12-22","2024-02-19",[3039],"Healthy Volonteers",[3017],{"intervention":3042,"totalTrials":164,"cells":3043},"Placenta pathological examination",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3050,"PHASE4":3052,"NA":3054},{"trials":3045,"activeCount":99},[],{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[],{"trials":3051,"activeCount":99},[],{"trials":3053,"activeCount":99},[],{"trials":3055,"activeCount":99},[3056],{"nctId":3057,"briefTitle":3058,"status":579,"phases":3059,"primaryCompletion":3060,"completion":3061,"start":3062,"enrollment":3063,"conditions":3064,"interventions":3066},"NCT04846686","Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.",[],"2022-12-31","2023-01-01","2022-06-01",35,[3065],"Preeclampsia",[3042],{"intervention":3068,"totalTrials":164,"cells":3069},"opioid",{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3071,"activeCount":99},[],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[],{"trials":3077,"activeCount":99},[],{"trials":3079,"activeCount":99},[],{"trials":3081,"activeCount":99},[3082],{"nctId":3083,"briefTitle":3084,"status":579,"phases":3085,"primaryCompletion":3086,"completion":3086,"start":3087,"enrollment":647,"conditions":3088,"interventions":3089},"NCT01303471","Pain Assessment During General Anesthesia",[91],"2012-01","2011-11",[2128],[3068],{"intervention":3091,"totalTrials":164,"cells":3092},"Caspofungin",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[],{"trials":3098,"activeCount":99},[],{"trials":3100,"activeCount":99},[],{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[3105],{"nctId":3106,"briefTitle":3107,"status":579,"phases":3108,"primaryCompletion":3109,"completion":3110,"start":3111,"enrollment":727,"conditions":3112,"interventions":3114},"NCT02596984","Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients",[91],"2018-05","2018-05-31","2015-03-16",[3113],"Shock",[3091],{"intervention":3116,"totalTrials":164,"cells":3117},"cimetidine arrow",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3119,"activeCount":99},[],{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"trials":3127,"activeCount":99},[],{"trials":3129,"activeCount":99},[3130],{"nctId":3131,"briefTitle":3132,"status":579,"phases":3133,"primaryCompletion":2125,"completion":2125,"start":3134,"enrollment":3135,"conditions":3136,"interventions":3137},"NCT00475059","Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients",[91],"2007-03",59,[1113],[3116],{"intervention":3139,"totalTrials":164,"cells":3140},"Surfactant administration until 2020",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[3153],{"nctId":3154,"briefTitle":3155,"status":579,"phases":3156,"primaryCompletion":3157,"completion":3157,"start":3158,"enrollment":2525,"conditions":3159,"interventions":3161},"NCT04775459","Surfactant Replacement Guided by Early Lung Ultrasound Score in Preterm Newborns With Respiratory Distress Syndrome",[],"2021-05-31","2021-01-01",[3160],"Preterm Birth",[3139,3162],"Surfactant administration since 2021",{"intervention":3162,"totalTrials":164,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3171,"PHASE4":3173,"NA":3175},{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[3177],{"nctId":3154,"briefTitle":3155,"status":579,"phases":3178,"primaryCompletion":3157,"completion":3157,"start":3158,"enrollment":2525,"conditions":3179,"interventions":3180},[],[3160],[3139,3162],{"intervention":3182,"totalTrials":164,"cells":3183},"RopivacaIne chlorhydrate",{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3188,"PHASE3":3190,"PHASE4":3192,"NA":3194},{"trials":3185,"activeCount":99},[],{"trials":3187,"activeCount":99},[],{"trials":3189,"activeCount":99},[],{"trials":3191,"activeCount":99},[],{"trials":3193,"activeCount":99},[],{"trials":3195,"activeCount":99},[3196],{"nctId":3197,"briefTitle":3198,"status":151,"phases":3199,"primaryCompletion":2806,"completion":3200,"start":3201,"enrollment":3202,"conditions":3203,"interventions":3205},"NCT02527577","Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.",[91],"2015-02","2010-04",39,[3204],"Liver Cancer, Adult",[3182],{"intervention":3207,"totalTrials":164,"cells":3208},"Amiodarone",{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3210,"activeCount":99},[],{"trials":3212,"activeCount":99},[],{"trials":3214,"activeCount":99},[],{"trials":3216,"activeCount":99},[],{"trials":3218,"activeCount":99},[],{"trials":3220,"activeCount":99},[3221],{"nctId":3222,"briefTitle":3223,"status":151,"phases":3224,"primaryCompletion":3225,"completion":3225,"start":611,"enrollment":1930,"conditions":3226,"interventions":3228},"NCT01649544","Comparison of Treatment of Atrial Fibrillation (AF) Between Surgical Ultrasonic Technology or Drug Therapy for Patients With AF Requiring Mitral Valve Surgery",[91],"2015-09",[3227,2251],"Mitral Valvulopathy",[3207],{"intervention":662,"totalTrials":164,"cells":3230},{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[],{"trials":3242,"activeCount":99},[3243],{"nctId":652,"briefTitle":653,"status":151,"phases":3244,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":3245,"interventions":3246},[91],[660],[662,69],{"intervention":3248,"totalTrials":164,"cells":3249},"Furosemide",{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3254,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[],{"trials":3257,"activeCount":99},[],{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[3262],{"nctId":3263,"briefTitle":3264,"status":151,"phases":3265,"primaryCompletion":3266,"completion":3266,"start":3267,"enrollment":3268,"conditions":3269,"interventions":3272},"NCT02800135","Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term",[91],"2018-03-21","2016-04-11",93,[3270,3271],"Critical Illness","Oliguria",[3248],{"intervention":3274,"totalTrials":164,"cells":3275},"blood sample and urine sample",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3284,"NA":3286},{"trials":3277,"activeCount":99},[],{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[],{"trials":3283,"activeCount":99},[],{"trials":3285,"activeCount":99},[],{"trials":3287,"activeCount":99},[3288],{"nctId":3289,"briefTitle":3290,"status":579,"phases":3291,"primaryCompletion":1833,"completion":1833,"start":1084,"enrollment":3292,"conditions":3293,"interventions":3295},"NCT02355314","Doppler-based Renal Resistive Index in Assessing Renal Dysfunction Reversibility in ICU Patients",[91],367,[3294],"Acute Kidney Injury",[3274]]